Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 17/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 14/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 11/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3624229 | 0.87 | RORC (0.48) | RORCNR1H3NR1I2NR1H2MLYCD | |
| SCHEMBL3624227 | 0.87 | RORC (0.48) | RORCNR1H3NR1I2NR1H2MLYCD | |
| SCHEMBL3624600 | 0.84 | RORC (0.46) | RORCNR1H3NR1I2NR1H2 | |
| SCHEMBL3620185 | 0.83 | RORC (0.46) | RORCNR1H3NR1I2NR1H2 | |
| SCHEMBL3624471 | 0.79 | EP300 (0.47) | RORCNR1H3NR1I2NR1H2EP300 | |
| SCHEMBL3626261 | 0.79 | RORC (0.53) | RORCNR1H3NR1I2NR1H2MLYCD | |
| SCHEMBL3621073 | 0.76 | RORC (0.46) | RORCNR1H3NR1I2NR1H2 | |
| SCHEMBL3621070 | 0.76 | RORC (0.46) | RORCNR1H3NR1I2NR1H2 | |
| SCHEMBL3615387 | 0.75 | RORC (0.49) | RORCNR1H3NR1I2NR1H2EP300 | |
| SCHEMBL3615393 | 0.75 | RORC (0.49) | RORCNR1H3NR1I2NR1H2EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392567-B1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2392567-B1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2392567-A1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | Bristol-Myers Squibb Company (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392567-A1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | Bristol-Myers Squibb Company (US) | 2011-12-07 | — | — | EP | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1951676-A2 | LXR MODULATORS | Brystol-Myers Squibb Company (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007050425-A2 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050425-A2 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093470-A1 | LXR modulators | NR1H2, NR1H3, RXRB | RORC 66/4885NR1H3 2/4885NR1I2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.